Overall, cemiplimab demonstrated a favorable benefit–risk profile in Japanese patients with squamous or non-squamous advanced NSCLC with no EGFR, ALK, or ROS1 aberrations. Here, ROS1 is linked to non-small cell lung carcinoma.